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Introduction 
 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease, 
clinically characterized by movement disorders, cognitive deficits, and psychiatric 
problems. Although George Huntington first described this condition in 1872 
(Huntington, 1872), the identification of the disease-gene and the characterization 
of the genotype/phenotype relationship belong only to the last three decades 
(Walker, 2007).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
HD is one of the most common among the rare neurogenetic disorders but 
epidemiological data differ from one ethnicity to another. HD is more frequent in 
Caucasian than in Asian and African populations (Rawlins, 2016). Global 
prevalence is reported as 10.85 affected individuals per 100 000 in Italy (Squitieri, 
2015). Highest incidences can be found in areas where a founder effect is 
recognised, as Tasmania (Pridnore, 1990) or the regions around Lake Maracaibo in 
Venezuela (Young, 1986). 
The gene responsible for HD is IT15 and it is located on the short arm of 
chromosome 4 (The HD Collaborative Research Group, 1993). The gene encodes 
the protein huntingtin (HTT), expressed in all human cells with highest 
concentration in Central Nervous System (DiFiglia, 1995). Mechanisms of action 
of this protein are poorly understood. HTT seems to indirectly regulate the 
transcriptional processes and participate in long- and short-range axonal transport. 
These functions could be essential for embryonic development in animals: 
homozygous knockout mice for IT15 exhibit embryonal lethality by day 8.5 (Nasir, 
1995). HTT has been supposed to regulate the production and vesicular trafficking 
of the brain-derived neurotrophic factor (BDNF) (Zuccato, 2001; Gauthier, 2004). 
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An increased cellular death rate can also be observed in HTT knockout animals and 
a possible antiapoptotic role has been hypothesized. This protein could bind and 
prevent the formation of the pro-apoptotic Hip1-HIPPI (Hip1 protein interactor) 
complex or directly block the activation caspase 3 and 9 (Gervais, 2002; Rigamonti, 
2001). 
The gene IT15 contains a variable number of CAG (Cytosine-Adenine-Guanine) 
trinucleotides within the exon 1. Healthy individuals have fewer than 36 CAG 
repeats and most commonly about 15–25 repeats. CAG trinucleotides result in a 
polyglutamine tract (poliQ) within the N-terminus of the HTT protein. When their 
number exceeds the threshold of 35, the protein loses its physiologic structure and 
function, causing the clinical manifestations of HD. CAG repeats that exceed the 
number of 28, show instability on replication and their size could increase during 
the meiosis, more in spermatogenesis than oogenesis (Duyao, 1993). A correlation 
exists between CAG repetitions, severity of neurodegenerative mechanisms, and 
the clinical features of HD (Rubinsztein, 1993). The higher is the number of CAG 
in the expanded allele, the longer is the pathological poliQ in the mutant HTT 
(mHTT), and the earlier is the age at onset (AO) and the faster the clinical course 
of the disease, due to a more severe diffuse neuronal impairment. According to data 
in larger cohorts of HD patients, the number of CAG repeats has been estimated to 
account for about 56%-70% of the variation in age of onset (Andrew, 1993; Snell, 
1993). Meiotic instability and correlation genotype-phenotype explain the 
phenomenon of anticipation, typical for HD and all the trinucleotide expansion 
disorders (Spinocerebellar ataxias, Dentato-rubro-pallido-luysian atrophy, X-
linked Spino-bulbar muscular atrophy): the AO becomes progressively earlier from 
a generation to the next (Ridley, 1988). 
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Pathological CAG expansion in IT15 confers toxic functions to HTT. N-terminal 
fragments (containing the expanded poliQ), full-length mHTT monomers, 
oligomers, and large mHTT aggregates coexist in HD pathogenesis and disrupt 
multiple cellular pathways (Labbadia, 2013). MHTT shuttles into the nucleus where 
it affects the recruitment of RNA polymerase II and modifies gene expression 
through the binding of many transcription factors and cofactors, including CREB-
binding protein (CBP), p300/CBP-associated factor (p/CAF), p53, SP1, TAFII130, 
and PQBO1 (Seredenina. 2012; Okazawa, 2003). MHTT associates with the outer 
membrane of mitochondria, impairing its functions: it reduces energy production 
and membrane potential, alters calcium homeostasis, enhances oxidative stress, and 
triggers the caspase-mediated apoptotic pathways (Mochel, 2011; Browne, 1997). 
MHTT dysregulates mitochondrial biogenesis and function through effects on 
PGC-1a gene expression, and impedes retrograde and anterograde mitochondrial 
trafficking along axons (Cui, 2006). Dysfunction of the ubiquitin–proteasome 
system (UPS) has been demonstrated in HD (Li, 2011; Orr, 2008). Aggregates of 
mHTT accumulate into the cytosol where they sequestrate the key UPS components 
and prevent delivery of misfolded proteins to the nuclear proteasome (Park, 2013). 
These inclusions can also reduce the levels of HSP70 and DNAJ chaperons, through 
a combination of sequestration and transcriptional dysregulation, disrupting the 
cellular protein homeostasis (Hay, 2004). MHTT dramatically impairs 
neurotransmitters release at presynaptic junctions by physically impeding axonal 
transport and by reducing the efficiency with which synapse-bound cargo can be 
loaded onto microtubules (Morfini, 2009). 
Although the presence of mHTT is widely deleterious for the Central Nervous 
System, medium-sized spiny neurons (MSNs) of the striatum exhibit enhanced 
vulnerability (Ferrante, 1991). Possible explanations consider both susceptibility to 
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loss of BDNF neurotrophic support from cortical-striatal fibres and, conversely, 
sensitivity to excitotoxicity arising from cortical glutamatergic projections 
(Okamoto, 2009; Zuccato, 2009). At a later stage, pathological processes also 
affects other brain regions, including cerebral cortex (layers III, V, and VI), 
hippocampus, thalamus, globus pallidus, subthalamic nucleus, substantia nigra, 
white matter, and cerebellum (Vonsattel, 2008). 
From a histopathological point of view, even before the symptomatic 
manifestations of HD, immunohistochemical analyses demonstrate the presence of 
aggregates of polyubiquitinated mHTT that can form neuronal intranuclear or 
cytoplasmic and neuropil extranuclear inclusions both in the striatum and 
throughout the cortex (Gutekunst, 1999). In the last stages, cellular death processes 
and reparative gliosis phenomena can be observed.  
The onset of HD is conventionally defined as motor onset and the typical motor 
disorder is represented by choreic movements. 70% of HD patients are believed to 
have chorea at onset or during the clinical course of disease (Gudesblatt, 2011). As 
defined by Sanger, chorea is an ongoing random-appearing sequence of one or more 
discrete involuntary movements or movement fragments. Movements appear 
random due to variability in timing, duration, or direction (Sanger, 2010). At HD 
onset, choreic movements appear subtle, mild, and limited to face and/or distal 
extremities. They are usually worsened by anxiety and psychological stress and 
subsides during sleep. HD patients attempt to disguise chorea by incorporating it 
into a purposeful activity and this causes a condition of “restlessness”; as the disease 
worsens, chorea may become more proximal and involve the trunk, impairing gross 
motor coordination skills, gait and balance. Another pathognomonic finding in HD 
is the motor impersistence, which is the inability to maintain a voluntary muscle 
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contraction at a consistent level (Gordon, 2000). This difficulty leads to changes in 
position and sometimes compensatory repositioning, contributing to the HD 
patients’ overactivity. Motor impersistence is independent of chorea and is linearly 
progressive (Reilmann, 2001). Oculomotor abnormalities are well recognised in 
HD and can sometimes anticipate the choreic disorder. Both saccades and smooth 
pursuit movements may be abnormal: the first can be slow or reduced in latency 
and amplitude, the second are jerky or incomplete more frequently (Lasker, 1997). 
Dystonic postures and parkinsonian manifestations (mainly bradykinesia and 
rigidity) may coexist with chorea and participate to the motor decline during the 
disease progression. Their prevalence is greater in the juvenile forms of HD 
(Westphal variant of HD) or in the latest stage of HD, when chorea becomes less 
apparent (Nance, 2001). 
Psychiatric and behavioural problems combine with motor symptoms in a 
variable percentage of about 33%-76% and their expression is very variable (van 
Duijn, 2007). Mood depression is the most frequently reported condition and its 
prevalence amounts to more than twice that found in general population. Depressive 
symptoms frequently appear precociously and diminish during the middle and later 
stages of the disease. Around 10% of HD patients report suicide attempt but 
depression is not always the cause (Paulsen, 2005). Suicidality can be sometimes 
considered as expression of impulsive behaviour. In association or not with 
depression, HD patients may suffer from apathy, anxiety, and obsessive-
compulsive behaviour. Irritability is another common sign and it often occurs in the 
earlier stages. Its severity varies enormously from serious disputes to physical 
aggression (van Duijn, 2007). Psychosis is more frequent in the latest stages and it 
is associated with a more relevant cognitive decline. Paranoid delirium and acoustic 
hallucination characterize the clinical picture. 
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Cognitive problems complete the clinical triad of HD. Degree of severity and 
time at onset differ from one patient to another. The first cognitive alterations 
typically involve the executive function. Mind flexibility, judgement capability, and 
planning skills are first compromised; long-term memory and language are initially 
spared (Snowden, 2017). In the latest stages of disease, a progression in subcortical 
dementia is often described (Brandt, 1886). 
Diagnosis of HD is genetic and a pathological CAG expansion is researched in 
IT15 gene. Genetic test can be required for patients with a clinical picture suggestive 
of HD (diagnostic test) or for healthy individuals with a positive familial history of 
HD (predictive test). Neuroimaging studies can strengthen the clinical suspicion. 
Routine MRI and CT show a loss of striatal volume and increased size of the frontal 
horns of the lateral ventricles in moderate-to-severe HD patients (Strober, 1984). 
F18-FDG-PET could show a striatal and cortical reduction of radiotracer uptake 
already in the early stages of disease (Ciarmiello, 2006).  
No therapy is currently available to delay the onset of symptoms or prevent the 
progression of the disease but symptomatic treatment may improve the quality of 
life and prevent complications. Choreic movements should be treated 
pharmacologically only if they become disabling to the patient and tetrabenazine, a 
dopamine-depleting agent, is the most commonly used drug for this purpose. 
Selective serotonin reuptake inhibitors (SSRIs), Serotonin–norepinephrine 
reuptake inhibitors (SNRIs), tricyclic antidepressants, mood stabilizer drugs, and 
typical and atypical neuroleptics are variably chosen for the control of psychiatric 
and behavioural problems (Frank, 2014). No specific treatments exist for the 
cognitive deficits in HD. Experimental therapies, aimed to avoid the expression of 
the mHTT, are being tested in animal models and human trials. 
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Perceived motor, cognitive and psychiatric onset in Huntington’s 
disease: a correlation analysis. 
 
Clinical attention has been historically directed towards motor symptoms in HD 
although motor abnormalities represent only one aspect of the clinical triad of the 
disorder. 
Today again HD onset is considered as motor onset, patients without motor 
symptoms are defined prodromal, and genetic test is considered predictive although 
a patient with a positive familial anamnesis for HD, shows behavioural problems 
or describes attentional deficits. In experimental trials, inclusion criteria exclusively 
consider the motor onset and primary end-points look at a change in motor status.  
Only in the last decade, cognitive and psychiatric problem have received the 
proper attention, mainly due to the work of the PREDICT-HD study group. Now 
we know that cognitive and psychiatric symptoms are equally relevant to motor 
problems in HD and can compromise the quality of life of the patients and their 
caregivers. They sometime represent the more relevant problems to manage in HD 
clinical course. 
Cognitive and psychiatric impairments may precede choreic movements or other 
movements disorders in HD by a decade. 
Frontal functions are first impaired in HD and related to basal ganglia-
thalamocortical circuits dysfunctions. HD patients early experiment difficulties in 
problem solving, events planning, and decision making processes. A condition of 
mild cognitive impairment, due to the impairment of these functions, is then 
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recognisable, presenting in up to half of premanifest persons close to motor 
diagnosis (Duff, 2010). 
Before the onset of motor symptoms, cognitive alteration can progress and 
become a self-perceived problem, able to interfere in the functional levels (Paulsen, 
2013). 
Beglinger and her colleagues conducted one of the most detailed analyses 
involving predictors of patient-centered outcomes and reported that performance on 
the Stroop Interference Task was associated with functional loss for the ability to 
manage finances, drive safely, supervise children, volunteer, and grocery shop. The 
Symbol Digit Modalities Test was associated with inability to grocery shop and use 
public transportation (Beglinger, 2010). 
Anxiety and depression often represent the first psychiatric problems in HD. 
Since the onset, changes can be appreciated in behaviour modalities and interaction 
with family members and friends. Increasing difficulty in managing emotions 
sometimes leads to aggressive outbursts and “catastrophic reactions” (Almqvist, 
1999). Anxiety can manifest with psychosomatic symptoms, such as 
gastrointestinal problems or insomnia, which need symptomatic treatment. (Verny, 
2007).  
Apathy, irritability, and depression seem to worsen over time in the earliest 
stages of HD (Stage I and II), and only apathy continued to progress with disease 
progression into Stages II–IV (Craufurd, 2001). In another study, a cohort of 45 
prodromal gene mutation carriers was studied over an interval of 3.7 years: all the 
psychiatric problems increased but the greatest changes were noted in Irritability 
and Hostility (Kirkwood, 2002). More recently, Tabrizi and colleagues followed 
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120 prodromal Huntington disease gene mutation carriers and reported worsening 
apathy over 36 months (Tabrizi, 2013). 
Follow-up of the psychiatric problems in HD can be biased the awareness of the 
symptoms. The PREDICT-HD study group evidenced that companions of HD 
mutation carriers also report greater psychiatric symptoms over time compared to 
affected individuals. It is important to note that in HD mutation carriers who do not 
yet have motor diagnosis, decreased awareness of both motor (McCusker, 2010) 
and psychiatric (Duff, 2010) symptoms have been documented. 
A correlation between CAG repeats number and motor onset is well-known in 
HD; a little is reported about the correlation between CAG repeats in pathological 
IT15 allele and non-motor onset or if motor onset is associated to the occurrence of 
cognitive deficit or psychiatric problems. Our study is aimed to investigate these 
aspects in 188 patients with HD. 
 
Patients and methods 
 
One hundred and eighty-eight patients (96 M, 92 F) with HD have been enrolled 
in this study. Only HD patients with available data on age, sex, age at symptom 
onset, mutant CAG repeat size were included in this study. 
In the examined cohort, the expanded trinucleotide repeats ranged from 40 to 63 
with a mean (± SD) of 44.95 ± 3.63 CAGs. 
Age at symptoms in HD cohorts was defined as the age at which the first signs 
of HD appeared, distinguish between motor disturbances, psychiatric problems, and 
cognitive decline. The time at onset of motor (AMO), cognitive (ACO), and 
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psychiatric problems (APO) has been anamnestically deduced, interweaving the 
patients and their caregivers. For the psychiatric problems, time at onset was 
investigated about the occurrence of Depression, Irritability, Violent or Aggressive 
Behaviour, Apathy, Perseverative/Obsessive Behaviour, and Psychotic symptoms.  
 
Statistical Analysis 
As the relation between AO and mutant CAG repeat size is known to be 
exponential (Langbhen, 2004), we used the logarithmic transform of AO (AMO, 
ACO, APO) as dependent variable. The sizes of the mutant CAG repeats in IT15 
gene has been used as predictor variables.  
Univariate linear regression analyses will be first performed to determine the 
effect of the expanded HTT allele on AMO, ACO, and APO. A correlation analysis 
was conducted to study the relationship between the modalities of AO. 
 
Results 
Onset data in HD patients are summarized in Table 1.1. For 93.08%, 68.08%, 
and 92.08 of HD patients a motor, cognitive and psychiatric onset was respectively 
datable. For 30.85%, 3.72%, and 37.76% of HD patients the first symptoms were 
respectively only motor symptoms, cognitive deficits, or psychiatric problems. In 
26.67% of our cohort, there was a combination of these symptoms at onset. 
A regression equation used to model AO of HD patient is LAO = α + βX, where 
X is the expanded CAG repeat length and LAO is the natural log of AO.  
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First, we plotted the IT15 pathological CAG repeat length for the longer HD 
(CAGsHD) allele against the LAO for each individual in our cohort. For the 
logarithmic AMO, regression equation was LAO = 2.80 – 0.03 CAGsHD , Pearson’s 
r was -0.80, and r2 value was 0.65 (p < 0.01).  For the logarithmic ACO, regression 
equation was LAO = 155.51 – 2.43 CAGsHD, Pearson’s r was -0.73, and r2 value 
was 0.54 (p < 0.01). For the logarithmic APO, regression equation was LAO = 2.56 
– 0.02 CAGsHDl, Pearson’s r was -0.55, and r2 value was 0, 30 (p < 0.01). 
When the psychiatric onset symptoms were singularly studied, using as 
dependent variable their logarithmic time at onset and CAG repeats expansion as 
predictor variable, statistically significant (p < 0.01) regression models were 
obtained for all the psychiatric onset modalities with the exception of Psychiatric 
Symptoms. Regression equation, Pearson’s r and r2 value are summarised in Table 
1.2. 
In the correlation analysis among modalities of onset, all the correlation were 
statistically significant. A higher rho value was obtain between motor and cognitive 
onsets (ρ = 0.92); lower was the rho values between motor and psychiatric onsets 
(ρ = 0.74) and between cognitive and psychiatric (ρ = 0.71). When the single 
psychiatric domains were considered, the higher correlations with motor and 
cognitive onsets concerned Apathy and Perseverative/Obsessive Behaviour. When 
the single psychiatric domains were compared among them, the stronger 
correlations were those among Depression, Irritability and Violent or Aggressive 
Behaviour. Correlation analyses results are reported in Table 1.3. 
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Discussion 
 
Our study aims to investigate the dependence of motor, cognitive and psychiatric 
onsets from CAG repeats length in IT15 pathological allele and to study the 
correlation among these several modalities of clinical debut. The study has analysed 
these data in a large cohort of Italian HD patients. We have used anamnestic data, 
referring to the onset perceived from patients and their companions. Our study 
doesn’t report alterations in the subclinical phase and we think that our results may 
be closer to the daily life of HD patients. This type of source data could represent a 
potential study bias. At same time, the problem of patients’ awareness could 
interfere with the results. To limit this bias and to have a more accuracy of data, we 
have required the presence of the companion during the interview.   
In our patients, psychiatric and motor problems often represent the first 
symptoms, alone or in combination. The isolate cognitive onset is very rare. 
Association between onset modalities has been demonstrated through a correlation 
study. The stronger correlation is that between motor and cognitive onset: the earlier 
is the motor onset, the earlier are the cognitive problems. This association can be 
related to mechanism that are involved both in motor symptoms occurrence and 
cognitive problems debut: the basal ganglia-thalamocortical circuits dysfunctions. 
Lower but always consistent correlations are present between psychiatric onset and 
motor onset and between cognitive onset and psychiatric onset.  However, when a 
subanalysis was performed in relation to the different psychiatric symptoms, we 
have found that Perseverative/Obsessive Behaviour and Apathy have considerable 
positive correlation levels with motor and cognitive onsets, due to the same 
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mechanisms, the alteration of the connections between basal ganglia and prefrontal 
cortex (Huey ED, 2008; Lewy 2006). 
Our study confirm the strength correlation between CAG repeats length and 
motor onset. In this study CAG onset accounts for the 65% of variability in motor 
onset. Our results confirm data in literature. We evidenced that also cognitive onset 
can depend from CAG repeats in IT15 pathological allele: the length accounts for 
the 54% of variability in ACO. Onset in cognitive changes has been significantly (r 
= 0.57) associated to CAG repeats in the past literature (Andrew, 1993). The lower 
dependence degree between CAG repeats length and AO is that for psychiatric 
onset. CAG repeats number accounts only for the 30% in variability of APO. Also 
in this case we confirm data reported in other studies. Andrew et al. first evidence 
a statistically significant correlation (r = 0.51) between CAG and psychiatric onset 
(Andrew, 1993) and later studies found that the 31%-50% of variability in 
psychiatric onset is explained by CAG length (Squitieri, 2001, Vassos, 2008). The 
low dependence levels that we find, could be related to the bias that we have already 
mentioned. Another problems is to differentiate psychiatric problems due to 
structural and functional alterations from those related to an endoreattive aetiology. 
However we have found that CAG expansion explains a different level of 
variability in onset for every different psychiatric domain examined: it accounts for 
the 60% and 50% in variability in onset for Apathy and Depression respectively. 
Our study demonstrates the relevance of cognitive and psychiatric onsets, due to 
their frequency in HD clinical course and correlation with motor onset. To 
recognise psychiatric or cognitive problems as HD onsets could favour the patients 
to an early access to the diagnostic course and to experimental drugs.  Variation in 
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cognitive and psychiatric variables has to represent recognised markers of 
pathology, similarly to motor factors. 
The study demonstrates that CAG length represents a relevant but not the only 
factor responsible for cognitive and psychiatric onsets variability, as reported for 
motor onset. Modifier factors which are recognise to modulate the motor onset, 
should be also investigated for the debut of cognitive and psychiatric problems.  
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Tables 
 
 
Table 1.1. Demographic and genetic data. 
 
 
 
Table 1.2. Regression equation.  
Results of fitting linear regression ln(AO) = A + B*(CAG)n. p value refers to the 
significance of the regression parameter (B) indexing the effect of repeat length. R 
square is the coefficient of determination and represents the proportion of the 
variance in the dependent variable that is predictable from the independent 
variable. 
 
 
Onset Sample n° α β p R square
MOTOR ONSET 170 0,03 2,80 < 0,01 0,65
COGNITIVE ONSET 125 -2,43 155,51 < 0,01 0,54
PSYCHIATRIC ONSET 163 -0,02 2,56 < 0,01 0,30
Depression 139 -0,02 2,68 < 0,01 0,49
Irritability 136 -0,02 2,55 < 0,01 0,34
Violent or Aggressive Behaviour 82 -0,02 2,35 < 0,01 0,23
Apathy 94 -0,02 2,75 < 0,01 0,60
Perseverative or Obsessive Behaviour 83 -0,02 2,66 < 0,01 0,43
Psychotic symptoms 29 -0,10 2,26 0,10 0,06
HD patients 
(96 M, 92 F)
Expanded IT 15 gene (CAG n° mean ± SD) 44,95 ± 3,63
Motor onset (years mean ± SD) 44,02 ± 10,83
Cognitive onset (years mean ± SD) 46,52 ± 11,69
Psychiatric onset (years mean ± SD) 41,43 ± 12,26
Onset of Depression (years mean ± SD) 43,42 ± 11,75
Onset of Irritability (years mean ± SD) 44,52 ± 12,10
Onset of Violent or Aggressive Behaviour (years mean ± SD) 43,87 ± 11,26
Onset of Apathy (years mean ± SD) 47,23 ± 11,96
Onset of Perseverative or Obsessive Behaviour (years mean ± SD) 45,06 ± 12,78
Onset of Psychotic symptoms (years mean ± SD) 47,53 ± 12,77
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Table 1.3. Correlation analysis among the different onset modalities. 
Within the cells the Pearson correlation r coefficients are reported. 
 ** p < 0.01; * p < 0.05 
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MOTOR ONSET - 0,92** 0,74** 0,80** 0,80** 0,71** 0,84** 0,84** 0,78**
COGNITIVE ONSET 0,92** - 0,72** 0,78** 0,78** 0,66** 0,86** 0,91** 0,74**
PSYCHIATRIC ONSET 0,74** 0,71** - - - - - - -
Depression 0,80** 0,78** - 0,99** 0,98** 0,86** 0,76** 0,72**
Irritability 0,80** 0,78** - 0,99** 0,98** 0,86** 0,76** 0,72**
Violent or Aggressive Behaviour 0,71** 0,66** - 0,86** 0,98** 0,76** 0,69** 0,74**
Apathy 0,84** 0,86** - 0,86** 0,86** 0,76** 0,81** 0,74**
Perseverative or Obsessive Behaviour 0,84** 0,91** - 0,76** 0,76** 0,69** 0,81** 0,56*
Psychotic symptoms 0,78** 0,74** - 0,72** 0,72** 0,74** 0,56** 0,67*
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Study of SCAs genes as disease modifier in Huntington’s disease 
 
As previously said, HD exhibits the typical phenomenon of genetic anticipation 
and the symptoms of the disease appear earlier and more severe in subsequent 
generations due to meiotic instability, which increases the CAG repeats number. 
However, the CAG repeat expansion accounts only for approximately 56%-70% of 
the variation in age at onset in the 40 to 55 CAG repeat range associated typically 
with adult onset (Andrew, 1993; Snell, 1993). It is therefore possible to imagine 
that modifier genetic variants that segregate independently from the primary 
mutation, may influence the AO, and probably also progression and severity of 
disease. 
Differences in genetic factors, environmental conditions and epigenetic patterns 
between individuals contribute to disease susceptibility and phenotypic variability. 
The study of these factors is more difficult as their contribution is limited and their 
number is large.  
For more than a decade, genetic modifiers in HD have been investigated, mostly 
utilizing the candidate gene approach. Several polymorphisms in various candidate 
genes have already been investigated as potential modifiers in HD patients. These 
studies have concentrated mainly on genes thought to be functionally relevant to 
the disease or to interact functionally with elongated HTT (Arning, 2012).  
The CAG repeat in non-expanded IT15 allele has been studied as possible 
genetic modifier factor in a cohort 921 patients with HD. In patient with 
pathological CAG repeats in the lower range, the increasing size of the normal CAG 
correlates with more severe symptoms. In patient with CAG repeats expansion in 
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the higher range, the non-expanded CAG correlates with a less severe clinical 
condition (Aziz 2009).  
Several genetic modifier factors have been researched analysing the glutamate-
mediated excitotoxicity. Altered NMDA receptor function and increased neuronal 
sensitivity to excitotoxicity are candidate mechanisms for selective neuronal 
dysfunction and degeneration in HD. The TAA repeat polymorphism in the 3’ 
untranslated region of GRIK2, which encodes the GluR6 subunit of the kainite 
receptor, is associated with earlier AO in HD. Single Nucleotide Polymorphisms 
(SNPs) in GRIN1 (Glutamate Ionotropic Receptor NMDA Type Subunit 1), 
GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A), and GRIN2B 
(Glutamate Ionotropic Receptor NMDA Type Subunit 2B) have been widely 
studied with contrasting results. To date, none of them has been functionally 
validated (Saft, 2011).  
Among the HTT-interacting proteins, TCERG1 and HAP1 have been studied as 
possible modifier factors. The imperfect (Gln-Ala)n repeat of the gene TCERG1, a 
transcriptional factor, has been screened in HD patients and the longest allele, 
which comprises 313 bp, has been associated to a slightly earlier AO (Holbert, 
2001). The polymorphism T441M in HAP1 has been considered protective because 
homozygous patient developed first symptoms 8 years later as compared with other 
patients (Wu, 2009). 
PPARγ coactivator 1α (PGC-1α) is a transcriptional coactivator that controls 
mitochondrial biogenesis and respiration. This protein has been studied as modifier 
gene because its functions are impaired due to the binding with HTT. In a large 
cohort of 854 European HD patients, the SNP s2970870 is associated to an earlier 
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onset in homozygous state while the polymorphism rs7665116 is responsible for a 
delay in onset (Che, 2011). 
Many other genes are candidates as modifier genetic factors and their association 
with HD requires further validations. They are implicate in the stress response and 
apoptosis, BDNF pathway, autophagy, and DNA repair mechanisms.  
In our study, we have decided to study seven SCAs genes (ATXN1, ATXN2, 
ATXN3, CACNA1A, ATXN7, PPP2R2B, and TBP) as modifying genes in HD due 
to genetic, pathological, and clinical similarities between HD and SCAs.  
 
Patients and methods 
 
Study Design 
Fifty HD patients (32 M – 18 F) and 100 healthy controls (HC) (47 M – 53 F) 
have been enrolled in this study. Only HD patients with available data on age, sex, 
age at symptom onset, mutant CAG repeat size were included in this study; for the 
control group, exclusion criteria was a positive pathological anamnesis and/or a 
positive familial anamnesis for neurodegenerative diseases.  
In the HD cohort, the expanded trinucleotide repeats ranged from 41 to 56 with 
a mean (± SD) of 44,42 ± 3,57 CAGs; CAG repeats number in the not expanded 
allele ranged from 9 to 25 with a mean (± SD) of 18,10 ± 3,22 CAGs 
Age at symptoms in HD cohorts was defined as the age at which the first signs 
of HD appeared, distinguish between motor disturbances, psychiatric problems, and 
cognitive decline. Motor onset was reported in all the HD patients and mean age at 
motor onset (AMO) was 46,17 ± 12,52 years. Cognitive onset was reported in 36 
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patients (72% of the HD cohort) and mean age at cognitive onset (ACO) was 47,56 
± 12,14 years. Psychiatric onset was reported in 43 HD patients and mean age at 
psychiatric onset (APO) was 43,40 ± 15,50 years. Regarding psychiatric onset, 
48,83% of HD patients had mood depression at onset, 23,25% had apathy, 39,53% 
had irritability, 18,60% had aggressiveness, and 6,97% had psychotic symptoms. 
For every HD subject and HC, CAG repeats will be sized in the larger allele of 
ATXN1, ATXN2, ATXN3, CACNA1A, ATXN7, PPP2R2B, and TBP genes, according 
the following modalities. 
 
Gene analysis 
Genomic DNA was extracted from blood samples using a standard phenol-
chloroform extraction. 
We determined the presence and precise size of the triplet repeat expansion 
according to an established fluorescent repeat-primed PCR protocol [REF]. 
PCR was performed using GeneAmp 9700 thermal reaction cycler (Applied 
Biosystems, Foster City, CA) in a 20 µL PCR mixture containing, 1 µL of extracted 
DNA (15-50 ng/µl), 0.5 µM of each forward primer fluorescently labeled with 
FAM, HEX , NED or PET as shown on Table 2.1, 1 X FailSafe Premix K containing 
PCR buffer, dNTPs and MgCl2 (Epicentre, Madison, WI, USA), and 1.0 unit of 
Platinum Taq DNA polymerase (Invitrogen Corporation, CA, USA). 
 Amplification was performed with an initial denaturation at 95°C for 5 minutes, 
followed by 35 cycles of denaturation at 94°C for 1 minute, annealing at 67°C for 
1 minute and extension at 72°C for 3 minutes and a final 15 minute extension at 
72°C.  
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One microliter of the generated PCR products was added to a mixture of 1.0 µL 
of LIZ 500  internal size standard (Celera diagnostics) and 9 µL of HiDi formamide 
(Invitrogen Corporation, CA, USA). The mixture was heated at 95ºC for 2 minutes 
and resolved by electrophoresis on an automated ABI Prism 3100 Genetic Analyzer 
using POP-6 (performance optimized polymer), on a 50 cm array (Applied 
Biosystems).  Samples were electrokinetically injected at 15 kV for 10 seconds and 
electrophoresed at 15 kV for 5400 seconds at 60ºC under filter set D. Raw data were 
analyzed with GeneMarker 1.85 (SoftGenetics, State College, PA), programmed 
for automatic allele calling based on fragment sizes. Allele calls on GeneMarker 
1.85 software were calculated using mean and 2 standard deviation of each allele 
type from different runs and by setting a minimum and maximum size range for 
each marker. 
 
Statistical Analysis 
As the relation between AO and mutant CAG repeat size is known to be 
exponential (Langbhen, 2004), we used the logarithmic transform of AO as 
dependent variable. The sizes of the mutant and normal CAG repeats in IT15 gene 
and the sizes of CAG repeats in ATXN1, ATXN2, ATXN3, CACNA1A, ATXN7, 
PPP2R2B, and TBP genes were used as predictor variables.  
Univariate linear regression analyses has been first performed to determine the 
effect of the expanded HTT allele and the normal HTT allele on AMO, ACO, and 
APO. Then, effects of the normal CAG repeats in seven SCA genes on AMO, ACO, 
and APO have been studied using linear regression analysis. Multiple regression 
analyses have been performed to study the additional effects on AO of SCAs genes, 
whose linear regression models have been found statistically significant. 
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As assessed by the Shapiro-Wilk test, CAG repeats in SCA genes did not meet 
the assumption for normality both in HD patients and in HC group. Accordingly, 
the Mann-Whitney U test was used to compare CAG repeats in ATXN1, ATXN2, 
ATXN3, CACNA1A, ATXN7, PPP2R2B, and TBP between HD patients and HC. 
 
Results 
Genetic data in HD patients and HC are summarized in Table 2.2. 
A regression equation used to model AO of HD patient is LAO = α + βX, where 
X is the expanded CAG repeat length and LAO is the natural log of AO.  
First, we plotted the IT15 pathological CAG repeat length for the longer HD 
(CAGsHDl) allele against the LAO for each individual in our cohort. For the 
logarithmic AMO, regression equation was LAO = 2.85 – 0.02 CAGsHDl, Pearson’s 
r was -0.79, and r2 value was 0.62 (p < 0.01).  For the logarithmic ACO, regression 
equation was LAO = 2.60 – 0.02 CAGsHDl, Pearson’s r was -0.6, and r2 value was 
0.60 (p < 0.01). For the logarithmic APO, regression equation was LAO = 2.50 – 
0.02 CAGsHDl, Pearson’s r was -0.42, and r2 value was 0,18 (p < 0.01). 
Second, we plotted the IT15 normal CAG repeat length for the shorter HD 
(CAGsHDs) allele against the LAO for each individual in our cohort. For the motor 
onset as well as for onset, regression model was not statistically significant. For the 
logarithmic ACO, regression equation was LAO = 2.60 – 0.02 CAGsHDl, Pearson’s 
r was -0.6, and r2 value was 0.60 (p < 0.01). 
When the logarithmic AMO was considered, the simple linear regression 
analysis provided a statistically significant model only for the larger CAG 
expansion of ATXN2 and CACNA1A genes. For ATXN2, the regression analysis was 
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LAO = 1.49 + 0.01 CAGsATNN2, Pearson's r value was 0.33, and r2 value was 0.08. 
For CACNA1A, the regression analysis was LAO = 1.10 + 0.03 CAGsCACNA1A, 
Pearson's r value was 0.34, and r2 value was 0.12. When the logarithmic ACO was 
considered in association to SCAs genes, simple linear regression models were not 
statistically significant. For the logarithmic APO, the only statistically significant 
simple regression linear model was that for the larger CAG expansion of ATXN2 
gene. Regression equation was LAO = 1.37 + 0.02 CAGsATNN2, Pearson's r value 
was 0.35 and r2 value was 0.12. 
Simple linear regression equations for IT15 and SCA genes are summarized in 
Table 2.3. 
When a multiple regression model was built using the CAGs of IT15 and ATXN2 
genes as predictor variables and the logarithmic AMO as dependent variable, the 
equation model was LAO = 2.62 - 0.02 CAGsHDl + 0.01 CAGsATXN2 and the 
adjusted r2 was 0.55. When the same predictor variables were used to obtain a 
multiple regression model to study the logarithmic APO, the regression equation 
was LAO = 2.02 – 0.01 CAGsHDl + 0.01 CAGsATXN2 and the adjusted r2 was 0.12.  
In both cases, the two variables (CAGsHDl and CAGsATXN2) do not add 
statistically significance to the prediction, p < .05. 
A multiple regression model was created to explain the logarithmic AMO 
starting from CAGs repeats of larger IT15 and CACNA1A genes. The regression 
equation was LAO = 2.48 – 0.02 CAGsHDl + 0.02 CAGsCACNA1A and the adjusted r2 
was 0.64. In this case, the two variables (CAGsHDl and CAGsCACNA1A) add 
statistically significance to the prediction, p < .05. 
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Statistical analysis demonstrated significant differences between HD patients 
and HC in CAG repeats number in ATXN1, CACNA1A, ATXN7, and PPP2R2B 
genes. A statistically significant increased number of CAG repeats in CACNA1A 
has been found in HD patients when compared to HD; contrarily, a statistically 
significant larger number in CAG repeats in ATXN1, ATXN7, and PPP2R2B has 
been found in HC compared to HD patients (Table 2.2). 
 
Discussion 
Disease onset is traditionally considered as motor onset in HD. Expanded CAG 
repeats account for more than 60% of AMO in HD; regression analysis in our cohort 
confirms this data. ACO and APO have not sufficiently studied in HD until today. 
Several studies have investigated the remaining variability in AMO studying 
different genetic and environmental factors. At the current time, genes encoding for 
proteins which interact with HTT or modulate the same pathways, represent the 
most promising factors. Also the DNA repair genes seem to have a relevant role in 
modifying the AMO.  
In this study we first investigate the possible role of SCA genes as modifier in 
AMO, ACO, and APO of HD patients. CAG repeats of normal alleles have been 
already considered when the non-expanded IT15 allele has been examined. These 
studies did not show any correlation with AMO and our regression analysis confirm 
this evidence; only the stratification of HD patients on the basis of the pathological 
CAG repeats number, made possible to obtain positive findings (Aziz 2009).We 
have chosen to study the seven SCA genes for several reasons. HD and SCAs share 
the same genetic basis, the expansion of CAG repeats in a specific gene. The 
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pathological processes responsible for HD and SCAs could often involve the same 
brain structures. As in HD, striatal atrophy can be evidenced in SCA3 and SCA17 
patients and dysfunction of the cortico-striato-thalamo-cortical loop is present also 
in SCA2, SCA6, and SCA8 (Park, 2015). On the other hand, cerebellum in HD 
shows a considerable atrophy, as well as a consistent loss of Purkinje cells and nerve 
cells of the fastigial, globose, emboliform and dentate nuclei (Rub, 2013). Clinically 
some SCA patients may present hyperkinetic movements, psychiatric problems and 
cognitive deficits; these SCAs, in particular SCA17, have been defined “HD-like 
syndromes” because they may be enter into differential diagnosis with HD 
(Martino, 2013). At the same time, HD patients can have cerebellar signs at onset 
or during the course of disease (Dong, 2013; Kageyama, 2003).  
The mHTT accumulates into the cell and sequesters other proteins; among these 
proteins, we can find the non-expanded HTT. Due to a structural homology 
(presence of a poliQ trait) we can suppose that other proteins can be included into 
these intracellular aggregates, such as the wild-type proteins encoded by SCA 
genes. Anatomopathological studies hypothesize that polar zippers, formed by 
polyglutamine expansions, may recruit small polyglutamine tracts. In SCA7 brains, 
inclusion of pathological expanded ataxin-7 are immunostained by anti-ataxin-3, 
showing the presence of normal ataxin-3 within pathological aggregates of 
expanded ataxin-7 (Zander, 2001). This is the first evidence that expanded polyQ 
proteins could sequestrate not expanded poliQ proteins. In HD neurons, interaction 
between proteins containing poliQ tracts could occur and modulate the pathological 
potential of mHTT aggregates. 
 Lastly a pathological interaction between IT15 and SCA genes has been already 
demonstrated. In a study aimed to investigate the modulation of the AO in SCAs 
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by CAG tracts in various genes, the authors found that the higher is the CAG repeats 
number (within normal range) of the longer IT15 allele in SCA3 patients, the latter 
is the disease onset (Tezenas, 2014). 
Our study doesn’t find extensive correlations between CAG repeats in SCA 
genes and AMO, ACO, and APO of HD. The only exceptions are represented by 
ATXN2 and CACNA1 for AMO, and ATXN2 for APO. When a multiple regression 
model was formulated and when the AMO was considered, a small additional effect 
(beyond that due to mutated IT15) was identified only for CACNA1A. CAG repeats 
in expanded IT15 and larger CACNA1A alleles account for 64% of AMO in HD 
patients.  
We also found differences in CAG repeats number in SCA genes between HD 
patients and HC. For ATXN2, ATXN3, and TBP there are no statistically significant 
differences between the two groups, whereas HD patients have a higher mean CAG 
number in CACNA1A and a lower mean CAG number in ATXN1, ATXN7, and 
PPP2R2B when compared to HC. It’s interesting to note how CACNA1A is the only 
SCA gene which seems to modify AO jointly with IT15. 
Statistically significant differences in CAG lengths of ATXN1, CACNA1A, 
ATXN7, and PPP2R2B genes between HD patients and HC may be expression of 
chromosomal instability. DNA chromosomal instability is typical in HD. Meiotic 
CAG instability is responsible for the phenomenon of anticipation. Interestingly, 
the expanded HD CAG repeat is also somatically unstable, undergoing progressive 
length increases over time: somatic instability is tissue-specific, with particularly 
high levels found in striatum and cortex and occurs in post-mitotic neurons. Global 
chromosomal instability has been demonstrated in HD: pluripotent stem cells 
(iPSC) were generated from primary dermal fibroblasts of HD patients and healthy 
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controls. Karyotype analysis revealed a significantly higher number of HD iPSC 
lines with genomic abnormalities when compared to control lines (Tidball AM, 
2016). 
CAG lengths appear increased in CACNA1A gene and reduced in ATXN1, 
ATXN7, and PPP2R2B genes; in ATXN2, ATXN3, and TBP genes, they don’t differ 
from those observed in HC. This variability could reflect the heterogeneity of the 
instability mechanisms: they could involve some genes or spare others, producing 
an expansion or contraction of DNA tracts.   
Although our study has analysed only a limited number of patients, we believe 
that these results could concur to the investigation of modifier factors in HD and 
the mechanisms of DNA instability, typical for this disorder. Further studies, 
conducted on larger HD patients’ cohorts, are needed to confirm our data. 
 
 
 
 
 
 
 
 
 
 
29 
 
Tables 
 
Primer 
name 
Forward primer sequence with 
fluorescent dye label on 5΄ 
Reverse primer sequence 
SCA1 
/5HEX/CTG AGC CAG ACG CCG 
GGA CAC AAG GCT GAG 
AGC CCT GCT GAG GTG CTG CTG 
CTG CTG CTG 
SCA2 
/5NED/GAGCCGGTGTATGGGCCCC
TCACCATGTCG 
AGC CGC GGG CGG CGG CTG CTG 
CTG CTG CTG 
SCA3 
/5PET/CCA GTG ACT ACT TTG ATT 
CGT GAA ACA ATG 
TCC TGA TAG GTC CCC CTG CTG 
CTG CTG CTG 
SCA6 
/5FAM/CAC GTG TCC TAT TCC CCT 
GTG ATC CGT AAG 
CGG CCT GGC CAC CGC CTG CTG 
CTG CTG CTG 
SCA7 
/5PET/TGT TAC ATT GTA GGA GCG 
GAA AGA ATG TCG 
CTG CGG AGG CGG CGG CTG CTG 
CTG CTG CTG 
SCA17 
/5HEX/CCT TAT GGC ACT GGA CTG 
ACC CCA CAG CCT 
TGC CAC TGC CTG TTG CTG CTG 
CTG CTG CTG 
 
Table 2.1. Primes used in PCR amplification. 
 
 HD patients HC p value 
IT15 (HD) 44.42 ± 3.57 / 18.10 ± 3.22 N.R.  
ATXN1 (SCA1) 35.72 ± 1.91 36.49 ± 1.60 < 0.01 
ATXN2 (SCA2) 26.16 ± 1.28 26.28 ± 1.11 0.12 
ATXN3 (SCA3) 26.83 ± 3.78 26.01 ± 5.23 0.353 
CACNA1A (SCA6) 17.18 ± 1.30 16.34 ± 1.19 < 0.01 
ATXN7 (SCA7) 24.02 ± 2.23 25.62 ± 2.50 < 0.01 
PPP2R2B (SCA12) 17.38 ± 2.26 18.87 ± 2.85 < 0.01 
TBP (SCA17) 35.86 ± 1.20 35.73 ± 1.05 0.479 
 
Table 2.2. Genetic data of HD patients and healthy controls (HC). 
Data are reported as mean ± SD (standard deviation). For IT15 gene, the sizes of 
the smaller and the larger allele are expressed; for the other genes, only the size of 
the larger allele is reported. P value refers to Mann-Whitney test for comparisons 
HD group vs HC group.  
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Table 2.3. Regression equations.  
Results of linear regressions ln(AO) = A + B*(CAG)n. p value refers to the 
significance of the regression parameter (B) indexing the effect of repeat length. R 
square is the coefficient of determination and represents the proportion of the 
variance in the dependent variable that is predictable from the independent 
variable. 
 
α β p R square
IT15 ( HD) normal -6,44 28,78 0,10 0,06
IT15 ( HD) expanded -0,03 2,85 < 0,01 0,62
ATXN1  (SCA1) 1,78 -0,01 0,57 0,01
ATXN2  (SCA2) 1,49 0,01 0,04 0,08
ATXN3  (SCA3) 1,72 -0,01 0,56 0,01
CACNA1A  (SCA6) 1,10 0,03 0,02 0,12
ATXN7  (SCA7) 1,26 0,02 0,34 0,02
PPP2R2B  (SCA12) 1,75 -0,01 0,48 0,01
TBP  (SCA17) 2,53 0,01 0,09 0,06
α β p R square
IT15  (HD) normal -8,63 32,35 0,01 0,08
IT15  (HD) expanded -0,02 2,60 < 0,01 0,36
ATXN1  (SCA1) 1,84 -0,01 0,50 0,01
ATXN2  (SCA2) 1,65 0,01 0,86 0,01
ATXN3  (SCA3) 1,78 -0,01 0,38 0,02
CACNA1A  (SCA6) 1,31 0,02 0,12 0,06
ATXN7  (SCA7) 0,95 0,03 0,12 0,07
PPP2R2B  (SCA12) 1,72 -0,01 0,73 0,01
TBP  (SCA17) 1,96 -0,01 0,61 0,01
α β p R square
IT15  (HD) normal 0,77 17,12 0,81 0,01
IT15 (HD) expanded -0,02 2,19 < 0,01 0,18
ATXN1  (SCA1) 2,14 -0,03 0,09 0,06
ATXN2  (SCA2) 1,37 0,02 0,04 0,12
ATXN3  (SCA3) 1,68 -0,01 0,67 0,01
CACNA1A  (SCA6) 1,27 0,01 0,32 0,02
ATXN7  (SCA7) 1,25 0,01 0,59 0,01
PPP2R2B  (SCA12) 1,52 0,01 0,66 0,01
TBP  (SCA17) 1,61 0,01 0,99 0,01
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Peripheral markers of autophagy in Huntington’s disease 
 
Protein homeostasis is an indispensable requirement for neuronal survival and 
the synthesis of new proteins strictly follows the removal of damaged proteins. 
Ubiquitin–proteasome system (UPS) and autophagy represent the cellular 
mechanisms responsible for proteins degradation. 
The UPS is the principal pathway for the clearance of short-lived, damaged, and 
misfolded proteins in the nucleus and cytoplasm (Dantuma, 2014). Ubiquitination 
and proteasomal degradation are the two separate and consecutive processes of UPS 
(Kleiger, 2014). An enzymatic cascade composed of ubiquitin activator, conjugase, 
and ligase catalyzes the covalent attachment of ubiquitin to a substrate protein. 
Multiple rounds of ubiquitination lead to the formation of a polyubiquitinated chain, 
which can function as a signal for degradation by the proteasome, a multisubunit 
enzyme complex composed of a 20S core particle and 19S regulatory particles, at 
one or both ends. The proteasome unfolds substrates and threads the polypeptide 
chains through the inner channel, where they are cleaved into short peptides 
(Bhattacharyya, 2014). Following their release from the barrel, peptides are rapidly 
processed into amino acids by cellular aminopeptidases and recycled (Reits, 2003). 
Autophagy is a highly selective lysosomal mediated degradation process. Three 
major types of autophagy have been described in mammalian cells: 
macroautophagy, microautophagy and chaperone mediated autophagy (CMA). 
Macroautophagy is the only process that can mediate the degradation of larger 
substrates such as organelles, microbes and protein aggregates. (Lamark, 2012). It 
requires the isolation of substrates within a double membrane bound vesicles to 
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form the autophagosomes and, later, the fusion between autophagosomes and 
lysosome.  
HD is characterized by cellular and nuclear accumulation of considerable 
amounts of mHTT. UPS cannot efficiently degrade polyQ-expanded proteins, as 
components of the UPS are frequently found in polyQ aggregates (Glickman, 
2002). Failure of the UPS might lead to upregulation of autophagy via cross-talk 
between degradation pathways in the attempt by the cell to maintain normal 
proteostasis. One particular form of macroautophagy, called aggrephagy, is 
responsible for the selective elimination of accumulated and aggregated 
polyubiquitinated proteins (Yamamoto, 2011). 
Aggrephagy involves a myriad of proteins, but three of them seem to be critical 
for the selective degradation of aggregates: microtubule associated protein 1 light 
chain 3 (LC3), p62, autophagy-linked FYVE domain protein (Alfy) (Clausen 2010).  
LC3, encoded by the gene MAP1LC3, is the mammalian homolog of Atg8 in yeast. 
It is essential for autophagosome biogenesis/maturation and it also functions as an 
adaptor protein for selective autophagy (Lee, 2016).  The phosphatidyl-
ethanolamine conjugated form of LC3 (LC3-II) is the activated form and is widely 
used as an autophagy marker. P62, also called optineurin and encoded by the gene 
SQSTM1, is a protein that binds both ubiquitinated cargos and LC3II, and functions 
as a signaling hub and an autophagy adaptor. P62 links ubiquitinated cargo with the 
nascent autophagosome allowing the maturation of the phagosome and subsequent 
fusion with lysosomes (Kasturagi, 2015). Alfy, encoded by the gene WDFY3 is an 
autophagy scaffold protein that binds p62 and is required for the autophagic 
degradation of cytoplasmic ubiquitin-positive inclusions (Lee, 2016). After LC3, 
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Alfy and p62 binding, the autophagolysosome can be closed and the degradation of 
aggregates takes place (Filimonenko, 2010). 
Although aggrephagy levels are preserved and even increased in HD, reports of 
cerebral biopsies from patients showed significant abnormalities in compartments 
of the vescicular-endocity pathway, noting an abnormal proliferation of lysosomes, 
HTT-positive autophagic vacuoles, and autophagolysosomes, as well as 
documenting disruption of the Golgi apparatus and disorganization of the 
endoplasmic reticulum (Tellez-Nagel, 1974). Therefore, the observed expansion of 
macroautophagy in HD cell is not accompanied by an expected increase in 
autophagy-mediated degradation. Cuervo et al. have explained this contradiction by 
demonstrating significant alteration in macroautophagy cargo recognition in HD 
cell cells, which leads to formation of empty autophagosomes (Martinez-Vicente, 
2010).   
Based on the presence of aggregated in polyQ diseases, we hypothesized an 
increase in peripheral autophagy markers. We designed a clinical study to measure 
the expression levels of MAP1LC3, SQSTM1 and WDFY3 in patients with HD, and 
to compare these levels with those found in healthy controls and patients suffering 
from SCA 2 (spino-cerebellar ataxia type 2), another polyglutamine repeat disorder. 
Expression levels were measured in peripheral blood mononuclear cells (PBMCs) 
as they represent an easily accessible and repeatable matrix for clinical use such as 
clinical trials or observational studies. 
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Patients and Methods 
 
Study Design 
This was a cross-sectional observational study to examine autophagy markers in 
patients with HD, SCA2 and in healthy individuals. Patients and controls were 
consecutively enrolled at our research center.  
Inclusion criteria were a molecular diagnosis of HD or SCA2 for patients, and 
no evidence of known neurological and/or systemic disease for healthy controls.  
 
Clinical Scales 
The Scale for the Assessment and Rating of Ataxia (SARA) was used to assess 
the disability of patients with SCA2 (Schmitz-Hübsch, 2008) and the motor section 
of the Unified Huntington’s Disease Rating Scale (UHDRS) for HD (Huntington 
Study group, 1996). 
 
Gene analysis 
Gene expression measurement was performed as reported elsewhere (Saccà, 
2013). Briefly, peripheral blood mononuclear cells (PBMCs) were extracted from 
whole blood using Leucosep® tubes (Greiner bioone). Total mRNA from PBMCs 
was extracted with TRIzol® reagent (Thermofisher). Quality was checked with 
spectrophotometry and agarose-formaldehyde electrophoresis. One µg of total 
RNA was reversely transcribed (High Capacity RNA-to-cDNA, Thermofisher, 
USA), and 10% of cDNA product amplified using the TaqMan® Gene Expression 
35 
 
Master Mix. mRNA was quantified using Gene Expression Assays for 
MAP1LC3B, SQSTM1, WDFY3  (Thermofisher, ID n. Hs00917682_m1, 
Hs00177654_m1, Hs00698803_m1) and standardized by quantification of 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Thermofisher, MGB probe) 
as a reference gene. We chose GAPDH as a reference gene after comparing the 
stability of GAPDH, Hypoxanthine Phosphoribosyltransferase 1 (HPRT1), and 
actin beta (ACTB) using normfinder software.25 Relative expression was 
calculated with the efficiency-calibrated model.26 The entire procedure followed 
the Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments (MIQE) guidelines.27 
 
Statistical Analysis 
Baseline variables analysis was conducted using the ANOVA, for three-group 
comparison, and the unpaired t-test for two-group comparison. We used the chi-
square test to analyse gender distribution through groups. Normal distribution was 
tested with the Kolmogorov-Smirnov test. This showed a non-normal distribution 
for the relative expression of all tested genes, which was normalized through ln 
transformation. The difference in ln expression levels was analyzed with an 
Univariate General Linear Model that integrates a one-way ANOVA, phenotype as 
the only factor, and the Dunnett test as post-hoc. We used the Pearson’s correlation 
coefficient for correlation analysis, and corrected for multiple comparisons using 
the Bonferroni correction.  
P values of less than 0.05 were considered statistically significant. Statistical 
analysis was performed using SPSS version 23.0.0.1 running on macOS 10.11.6.  
36 
 
Results 
 
We enrolled 20 patients with HD, 20 patient with SCA2 and 20 healthy controls. 
Demographics and clinical data are shown in Table 3.1. Disease duration and CAG 
(number of CAG repeats in the expanded allele) were significantly shorter for HD 
as compared to SCA2 patients. The remaining variables did not differ between 
groups.  
MAP1LC3B (p = 0.046), SQSTM1 (p = 0.001), and WDFY3 (p < 0.001) 
significantly differed between groups (Fig. 3.1). HD patients showed higher 
expression levels of all three genes, whereas WDFY3 was the only overexpressed 
gene in SCA2 patients (Table 3.2). 
The following variables were used for the correlation analysis: age, disease 
duration, CAG2, clinical scale (UHDRS or SARA), Ln(expr_MAP1LC3B), 
Ln(expr_SQSTM1), and Ln(expr_WDFY3). Figure 3.2 shows the results for HD 
and controls. MAP1LC3B and SQSTM1 were positively correlated in all groups. 
SCA2 patients showed a positive correlation between MAP1LC3B and WDFY3, 
between WDFY3 and SQSTM1, between the SARA and both MAP1LC3B and 
SQSTM1. 
 
Discussion 
 
We report the first study measuring peripheral markers of autophagy in patients 
with HD and SCA2. Aggregate formation is a constant in all polyQ diseases, and 
due to the selectivity of aggrephagy in aggregate elimination, the value of peripheral 
markers as possible indicators of the process is evident.  
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MAP1LC3B, SQSTM1, and WDFY3 were all increased in HD patients, 
suggesting a profound and intense induction in autophagy, aimed at counteracting 
the formation of protein aggregates. In contrast, SCA2 patients had a more modest 
modification with higher expression levels of WDFY3 alone. 
This discrepancy may be due to the different pathological mechanisms of both 
diseases, as HD patients tend to form more aggregates than SCA2. Indeed, only 
cytoplasmic aggregates have a pathogenetic potential in SCA2, indicating a 
different nature of the aggregates themselves.  
It was speculated that aggregates in SCA2 are made of Golgi fragments, and not 
of insoluble protein aggregates, as seen in HD. If this is true, in SCA2 the 
aggrephagic cascade, that is initiated by the contact of p62 with ubiquitinated 
proteins, is less activated as compared to HD.15 In addition, MAP1LC3B 
expression is strongly correlated with the number of autophagosomes,16 and since 
the latter are typically normal in SCA2 patients, and increased in HD, it is intuitive 
why MAP1LC3B levels were normal in SCA2.17  
Recent evidence suggests that HTT is involved in the autophagic pathway in a 
specific way as it physically interacts with the autophagy cargo receptor p62 to 
facilitate its association with LC3 and with Lys-63-linked ubiquitin-modified 
substrates. The presence of empty autophagosomes in HD cells can be attributed to 
defective cargo recognition due to the presence of polyQ-htt in the inner part of the 
closing autophagosomes.18 According to our results, the increase in SQSTM1, 
WDFY3 and MAP1LC3B mRNA could be a compensatory mechanism in order to 
complete the autophagic process. Unfortunately this compensation is clearly not 
sufficient, as aggregates are not entirely removed and the disease still becomes 
manifest.  
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The absence of a clear correlation between clinical measures and markers of 
autophagy in HD patients, may prove that aggregate formation is independent of 
clinical parameters, or that autophagy is pushed to the maximum (i.e. it is saturated), 
so that correlation is lost. To support this, SCA2 patients, that have a lower level of 
aggregate formation, and limited increase in autophagy markers, show a correlation 
between disease severity and both MAP1LC3B and SQSTM1 expression.  This is 
also supported by the higher disease duration in SCA2 patients that may have 
contributed to observed correlation. 
Interestingly, MAP1LC3B and SQSTM1 expression were correlated throughout 
all phenotypes, including control individuals. This suggests that both genes may 
influence each other without influencing WDFY3, and that this mechanism takes 
place in physiological conditions as well as in the presence of aggregates.  
A limitation of the present report is the cross-sectional nature of the study, that 
does not help in understanding the relationship between aggrephagy markers and 
polyQ diseases. Due to the progressive nature of both diseases, measurements in 
the same patients at different time-points of the disease could help better understand 
if disease progression and aggrephagy stimulation proceed in parallel, or if the two 
are independent. The same study in pre-symptomatic patients could prove that 
aggrephagy is over stimulated before disease onset, and if higher expression levels 
are a protective factor against phenoconversion to diagnosed HD.  
In conclusion, our study shows that peripheral markers of autophagy are elevated 
in polyQ diseases, and that this is particularly evident in HD. These markers can be 
useful in future clinical trials aimed at modifying disease progression through 
different mechanisms, including stimulating autophagy. 
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Tables and Figures 
 
 
 
 
 
 
 
 
Table 3.1. Demographics and clinic data. 
Italicized values correspond to significant p values 
HD Huntington’s disease, SCA2 spinocerebellar disease type 2, UHDRS Unified 
Huntington’s Disease Rating Scale, SARA Scale for the Rating and Assessment of 
Ataxia; CAG2 number of CAG repeats in the expanded allele. Age was 
preliminarily tested with a one-way ANOVA (p = 0.032) and Bonferroni’s multiple 
comparisons test (*CNTRL vs HD; **CNTRL vs SCA2; ***HD vs SCA2). 
Differences in gender were tested with the chi-square test, differences in disease 
duration, CAG with an unpaired t test. 
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Table 3.2. Gene expression levels 
Italicized values correspond to significant p values 
HD Huntington’s disease; SCA2 spinocerebellar ataxia type 2, CI confidence 
intervals. Gene expression levels are shown as relative expression, and standard 
deviation in parenthesis. Statistical analysis was performed on ln transformed 
values and analyzed with the Dunnett’s post hoc test after passing the Univariate-
GLM. 
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Fig. 3.1. Gene expression levels.  
Gene expression levels are shown as relative expression, whiskers show standard 
error mean. *p<0.05; **p<0.01; ***p < 0.001. Statistical analysis was performed 
on ln transformed values and analyzed with the Dunnett’s post hoc test after passing 
the Univariate-GLM 
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Fig. 3.2. Correlation analysis.  
The figure shows correlations where p < 0.05 after Bonferroni correction for 
multiple comparisons. Correlation was performed using the Pearson’s correlation 
coefficient and corrected for multiple comparisons using the Bonferroni correction. 
HD Huntington’s disease, SCA2 spinocerebellar ataxia type 2, UHDRS Unified 
Huntington’s Disease Rating Scale, SARA Scale for the Rating and Assessment of 
Ataxia, DD disease duration. 
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